Mandi Murph, Ph.D.
Pharmaceutical and Biomedical Sciences
Pharmaceutical and Biomedical Sciences
Pharmaceutical and Biomedical Sciences
Post-doctoral fellow, University of Texas MD Anderson Cancer Center, Houston, TX 2005-2008
Ph.D. Molecular, Cellular Biology and Biochemistry, Georgia Institute of Technology 2005
B.S. Biology, Emory University 1999
Research Areas: Molecular mechanisms to prevent chemoresistance or prolong remission by extending time until chemoresistance develops in
Opportunities for Collaboration: Chemistry
Dr. Murph’s laboratory focuses on therapeutic questions of two diseases, melanoma and serous epithelial ovarian carcinoma. For both malignancies, treating patients is coupled with major clinical frustrations, like chemoresistance; this is where science can aid in developing therapeutics and molecular strategies to overcome such obstacles. Enormous progress has been made in the fight against breast and prostate cancer, and childhood leukemia that it is time all cancer subtypes mimic that success. Recently, drugs such as vemurafenib, dabrafenib, trametinib, ipilimumab, pembrolizumab and nivolumab, which treat melanoma, bolster the hope that additional options will soon become available.
Another example of medical therapeutic challenges occurs among women with ovarian cancer. These patients receive debulking surgery followed by adjuvant chemotherapy that reduces their tumors to an undetectable level. Essentially, treatment initially works very well and most patients enjoy a time of remission. However, this is deceiving since 75 to 85 percent of these women will return to the clinic within 18 to 24 months with refractory tumors. The Murph laboratory investigates this question in an attempt to find molecular mechanisms of exploration to either prevent chemoresistance from developing, or prolonging the period of remission by extending the time until chemo resistance develops in slow progressing dormant cells. Chemoresistance will also be a major challenge in melanoma patients. Thus, the development of chemoresistance in mammalian cells is a continuous problem requiring resolution that will ultimately benefit many cancer types.
Basiri B, Murph MM, Bartlett MG*. (2017) Assessing the Interplay between the Physicochemical Parameters of Ion-Pairing Reagents and the Analyte Sequence on the Electrospray Desorption Process for Oligonucleotides. J Am Soc Mass Spectrom. 2017 Apr 12. PMID: 28405940. IF 2016: 2.786
Basiri B, van Hattum H, van Dongen WD, Murph MM, Bartlett MG*. (2017) The Role of Fluorinated Alcohols as Mobile Phase Modifiers for LC-MS Analysis of Oligonucleotides. J Am Soc Mass Spectrom. 2017 Jan;28(1):190-199. PMID: 27644940. IF 2016: 2.786
Nguyen HT, Jia W, Beedle AM, Kennedy EJ, Murph MM. (2015) Lysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p. PLoS One. 2015 Sep 29;10(9):e0139489. PMID: 26418018
Kuppa, S and Murph, MM*. (2016) Platinum agents, taxanes and PARP inhibitors: the ovarian cancer drug formulary and molecular mechanisms of chemoresistance emergence.
Alshamrani, A.A., Franklin, J.L., Beedle, A.M. and Murph, M.M*. (2016) Inhibiting Lactate Dehydrogenase A Enhances the Cytotoxicity of the Mitochondria Accumulating Antioxidant, Mitoquinone, in Melanoma Cells. Chapter in “Human Skin Cancer, Potential Biomarkers and Therapeutic Targets”, edited by Miroslav Blumenberg, ISBN 978-953-51-2711-6, Print ISBN 978-953-51-2710-9. DOI: 10.5772/64231. October 19, 2016
Altman MK, Alshamrani AA, Jia W, Nguyen HT, Fambrough JM, Tran SK, Patel MB, Hoseinzadeh P, Beedle AM,Murph MM. (2015) Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells. Cancer Lett. 2015 Aug 28. pii: S0304-3835(15)00541-8. PMID: 26319900
Murph, M.M., Jiang, G.W., Altman, M.K., Jia, W., Nguyen, D.T., Fambrough, J.M., Hardman, W.H., Nguyen, H.T., Tran, S.K., Alshamrani, A.A., Madan, D., Zhang, J. and Prestwich, G.D. (2015) Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma. Bioorg Med Chem. 2015 Jul 2. pii: S0968-0896(15)00548-9. PMID: 26190462
Wang Y, Ho TG, Franz E, Hermann JS, Smith FD, Henhly H, Esseltine JL, Hanold LE, Murph MM, Bertinetti D, Scott JD, Herberg FW, Kennedy EJ. (2015) PKA-type I Selective Constrained Peptide Disruptors of AKAP Complexes. ACS Chem Biol. ACS Chem Biol. 2015 Jun 19;10(6):1502-10. PMID: 25765284
Hooks, SB and Murph, MM. (2015) Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer. Future Med Chem. 2015 Aug 21:1-7. doi: 10.4155/fmc.15.81. Epub 2015 Aug 21. PMID: 26293348
Brindley, D.N., Benesch M.G.K. and Murph, M.M. (2015) Autotaxin: An Enzymatic Augmenter of Malignant Progression Linked to Inflammation. Chapter 12 in “Melanoma – Current Clinical Management and Future Therapeutics.” Available from: Published April 1, 2015.
Jia, W., Tran, S.K., Ruddick, C.A. and Murph, M.M. (2014) The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells. Cancer Lett. 2014 Oct 7, article in press. PMID: 25304369
Liu S, Meng X, Chen H, Liu W, Liu W, Miller T, Murph M.M, Lu Y, Zhang F, Iurascu MG, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. (2014) Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 May 27. PMID: 24979294
Nguyen, H.T., Tian, G. and Murph M.M. (2014) Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol. 4(71): 1-12. PMID: 24782983
Ali Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB. (2013) Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS ONE. 8(3):e60185.
Ha T. Nguyen and Mandi M. Murph. (2013) DICER and MicroRNAs: Oncomirs are the Next Frontier of Oncogenes Affecting Cancer Etiology and Tumor Progression. “Oncogenes: Classification, Mechanisms of Activation and Roles in Cancer Development.” pp.85-124.
Altman, M.K., Nguyen, D.T., Patel, S.B., Fambrough, J.M., Beedle, A.M., Hardman, W.J. and Murph, M.M. (2012) Regulator of G-protein Signaling 5 reduces HeyA8 ovarian cancer cell proliferation and extends survival in a murine tumor model. Biochem Res Int. 2012;2012:518437. PMID: 22792465
Eun-Kyoung Breuer, Mandi M. Murph and Rolf J. Craven. Biochemical Pathways in Cancer. Biochemistry Research International. Volume 2012, Article ID 268504. Accepted October 2012.
Murph M.M. Autotaxin. The Encyclopedia of Cancer. January 2012. Springer Reference.
Murph M.M. Lysophosphatidic Acid. The Encyclopedia of Cancer. April 2012. Springer Reference. URL:
Breuer EK, Murph M.M. (2011) The Role of Proteomics in the Diagnosis and Treatment of Women’s Cancers: Current Trends in Technology and Future Opportunities. Int J Proteomics. Jan 1;2011. pii: 373584. PMID: 21886869
Nguyen, D., Nguyen, O., Zhang, H., Prestwich, G.D. and Murph, M.M. (2011). A Bromophosphonate Analogue of Lysophosphatidic Acid Surpasses Dacarbazine in Reducing Cell Proliferation and Viability of MeWo Melanoma Cells.Chapter in “Research on Melanoma – A Glimpse into Current Directions and Future Trends”, Murph, M.M. (Ed.), ISBN: 978-953-307-293-7. InTech.
Eun-Kyoung Yim Breuer and Mandi M. Murph. The role of proteomics in the diagnosis and treatment of women’s cancers: current trends in technology and future opportunities. Accepted in Advances in Proteomics: The Future of Cancer Management on April 7, 2011. Article in press.
Nguyen G.H., Murph M.M. and Chang J.Y. (2011) Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy may Fail in Lung and Esophageal Cancers. Cancers 2011; 3(1): 1232-1252. ISSN 2072-6694.
Hooks S.B., Callihan P., Altman M.K., Hurst J.H., Ali M.W., Murph M.M. (2010) Regulators of G-Protein Signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010 Nov 2;9(1):289. PMID: 21044322
Altman M.K., Gopal V., Jia W., Yu S., Hall H., Mills G.B., McGinnis A.C., Bartlett M.G., Jiang G., Madan D., Prestwich G.D., Xu Y., Davies M.A., Murph M.M. (2010) Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer. 2010 Jun 9;9(1):140. PMID: 20529378
Liu S., Murph M., Panupinthu N. and Mills, G.B. (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. Nov 15;8(22):3695-701. PMID: 19855166
Liu S., Umezu-Goto M., Murph M., Lu Y., Liu W., Zhang F., Yu S., Stephens L.C., Cui X., Murrow G., Coombes, K., Muller W., Hung M.C., Perou C.M., Lee A.V., Fang X., Mills G.B. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. Jun 2;15(6):539-50. PMID: 19477432